DBV Technologies (DBVT) Total Liabilities (2015 - 2026)
DBV Technologies (DBVT) posted Total Liabilities of $62.8 million for Q2 2026, up 7.53% sequentially from $58.4 million in Q1 2026, and up 9.78% YoY from $57.2 million in Q2 2025.
DBV Technologies (DBVT) Total Liabilities (2015 - 2026) Analysis & Trends
DBV Technologies has reported Total Liabilities for 12 years, with the latest figure at $62.8 million in Q2 2026.
- Quarterly Total Liabilities rose 9.78% year-over-year to $62.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $62.8 million (up 9.78% YoY) and the FY2025 annual result came in at $64.9 million, up 69.58% from the prior year.
- Total Liabilities climbed to $62.8 million in Q2 2026 per DBVT's latest filing, from $58.4 million in the prior quarter.
- Over five years, Total Liabilities peaked at $64.9 million in Q4 2025 and troughed at $34.2 million in Q1 2024.
- A 5-year average of $47.5 million and a median of $46.7 million in 2023 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2024 and 2025: Total Liabilities plunged 36.4% in 2024, then soared 69.58% in 2025.
- Over 5 years, Total Liabilities stood at $52.1 million in 2022, then dropped by 17.8% to $42.8 million in 2023, then decreased by 10.58% to $38.3 million in 2024, then soared by 69.58% to $64.9 million in 2025, then slipped by 3.24% to $62.8 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $62.8 million, $58.4 million, and $64.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | DBV Technologies | 6.08 Bn | 5.90 Bn | - | 62.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 62.80 Mn |
| Mar 31, 2026 | 58.40 Mn |
| Dec 31, 2025 | 64.90 Mn |
| Sep 30, 2025 | 57.64 Mn |
| Jun 30, 2025 | 57.21 Mn |
| Mar 31, 2025 | 47.69 Mn |
| Dec 31, 2024 | 38.27 Mn |
| Sep 30, 2024 | 39.02 Mn |
| Jun 30, 2024 | 35.10 Mn |
| Mar 31, 2024 | 34.24 Mn |
| Dec 31, 2023 | 42.80 Mn |
| Sep 30, 2023 | 45.79 Mn |
| Jun 30, 2023 | 53.28 Mn |
| Mar 31, 2023 | 53.83 Mn |
| Dec 31, 2022 | 52.06 Mn |
| Sep 30, 2022 | 36.07 Mn |
| Jun 30, 2022 | 40.56 Mn |
| Mar 31, 2022 | 35.52 Mn |
| Dec 31, 2021 | 47.45 Mn |
| Sep 30, 2021 | 54.03 Mn |